Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Yajie Fu, Yanzhi Zhou, Linhu Shen, Xuewen Li, Haorui Zhang, Yeqi Cui, Ke Zhang, Weiguo Li, Weidong Chen, Shizhen Zhao, Yunfu Li, Wenling Ye
Abstract
The global incidence rate of non-alcoholic fatty liver disease (NAFLD) is approximately 25%. With the global increase in obesity and its associated metabolic syndromes, NAFLD has become an important cause of chronic liver disease in many countries. Despite recent advances in pathogenesis, diagnosis, and therapeutics, there are still challenges in its treatment. In this review, we briefly describe diagnostic methods, therapeutic targets, and drugs related to NAFLD. In particular, we focus on evaluating carbohydrate and lipid metabolism, lipotoxicity, cell death, inflammation, and fibrosis as potential therapeutic targets for NAFLD. We also summarized the clinical research progress in terms of drug development and combination therapy, thereby providing references for NAFLD drug development.